ALX Oncology (ALXO)
Develops evorpacept and ALX2004 for clinical-stage cancer studies.
5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO
5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,057,325 shares of the company's stock, valued at approximately $6,328,663,000. ALX Oncology makes up
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph. D. , After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointments of Scott Garland as Chairman of the Board of Directors (the "Board") and Michael Listgarten as General Counsel, effective immediately.
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 - - ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and Operating Officer - - Company to host webcast including presentation of ESMO Breast data by breast cancer expert Sara Hurvitz, M.
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 2,222,798 shares, a growth of 81.7% from the March 15th total of 1,223,050 shares. Currently, 2.1% of the shares of the company are sold short.
ALX Oncology Q4 Earnings Call Highlights
ALX Oncology (NASDAQ: ALXO) outlined progress across its two core programs-CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate ALX2004-while providing updated clinical timelines and financial runway during its fourth-quarter and full-year 2025 results call. Leadership update and execution focus Chief Executive Officer Jason Lettmann said the company's priority remains execution and positioned 2025 as a year that
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Corey Goodman Acquires 3,184,713 Shares of ALX Oncology (NASDAQ:ALXO) Stock
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) Director Corey Goodman acquired 3,184,713 shares of the business's stock in a transaction on Monday, February 2nd. The shares were bought at an average cost of $1.57 per share, for a total transaction of $4,999,999.41. Following the acquisition, the director owned 8,453,038 shares of the company's
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0%
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,047,613 shares, an increase of 32.0% from the November 30th total of 793,867 shares. Approximately 2.4% of the company's stock are sold short. Based on
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
- Combination of evorpacept plus rituximab and lenalidomide (R 2 ) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R 2 alone
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript
ALX Oncology Holdings Inc. ( ALXO ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Jason Lettmann - CEO & Director Barbara Klencke Conference Call Participants John Mills - ICR Inc. Daniel Bronder Jiale Song - Jefferies LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Presentation Jason Lettmann CEO & Director Thanks, everyone, and welcome to our Q3 2025 results. I appreciate everybody spending some time with us this morning, and I'm looking forward to this update.
ALX Oncology (ALXO) Expected to Announce Earnings on Friday
ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details
ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript
ALX Oncology Holdings Inc. (NASDAQ:ALXO ) Q2 2025 Earnings Conference Call August 12, 2023 4:30 AM ET Company Participants Alan Bart Sandler - Chief Medical Officer Harish Shantharam - Chief Financial Officer Jason W. Lettmann - CEO & Director Conference Call Participants Allison Marie Bratzel - Piper Sandler & Co., Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Roger Song - Jefferies LLC, Research Division Samuel Evan Slutsky - LifeSci Capital, LLC, Research Division Ting Liu - UBS Investment Bank, Research Division Yu He - H.C.
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.